Show simple item record

dc.contributor.advisor Azzazy, Hassan
dc.contributor.advisor Allam, Nageh
dc.contributor.advisor Basalious, Emad Mohsen, Karim 2017-07-13T08:14:12Z 2017-10-11T22:00:17Z Summer 2017 en_US 2017-07-13
dc.description.abstract Subarachnoid hemorrhage (SAH) is the leading cause of death in stroke patients who suffer from vasospasms with incidence of 70%. SAH prevents sufficient oxygen supply to the brain causing ischemia and death. FDA approved only nimodipine (NM) for treatment of vasospasm associated with SAH. Nevertheless, NM has poor pharmacokinetic properties, which limit its clinical efficacy. NM is susceptible to first-pass metabolism and has low solubility and thereby poor bioavailability. The objective of this study is to assess the nose-brain pathway in brain targeting of NM-loaded lipid nanocapsules (LNCs) after intranasal administration. Solvent-free phase inversion temperature technique was used to prepare NM-loaded LNCs. Design Expert 7 was used to establish D-optimal mixture design. The model evaluates the impact of individual and combined effects of three independent variables, X1 (Labrafac), X2 (Solutol HS 15), and X3 (water), on responses Y1 (particle size), Y2 (Zeta potential), Y3 (polydispersity index; PDI), Y4 (drug payload), Y5 (entrapment efficiency), Y6, Y7, and Y8 (in vitro drug release after 6, 24, and 48 h, resp.), and Y9 (solubilization capacity). NM-loaded LNC was optimized to increase the NM payload, decrease particle size, and fulfil suitable zeta potential, PDI, and in vitro drug release. The optimized NM-loaded LNC revealed narrow size distribution of PDI of 0.146 ± 0.045, small particle size of 35.94 ± 0.14 nm, 5 mg/mL drug payload, spherical morphology, and appropriate drug release profile initially and over a 3-month period. The in vivo pharmacokinetic assessment of optimized NM-loaded LNC revealed absolute bioavailability of NM in brain (99.5%) and plasma (102.6%) in Wistar rats after intranasal administration of NM-loaded LNCs with reference to the IV administered NM solution. Finally, intranasal administration of NM-loaded LNCs supported safe and effective practice to deliver NM via intranasal route to the brain via systemic pathway attributed with NM BBB enhancement. en_US
dc.format.extent 128 p. en_US
dc.format.medium theses en_US
dc.language.iso en en_US
dc.rights Author retains all rights with regard to copyright. en
dc.subject Nimodipine en_US
dc.subject Lipid Nanocapsules en_US
dc.subject Brain targeting en_US
dc.subject.lcsh Thesis (M.S.)--American University in Cairo en_US
dc.title Lipid Nanocapsules for brain targeting of Nimodipine en_US
dc.type Text en_US
dc.subject.discipline Nanotechnology en_US
dc.rights.access This item is restricted for 3 months from the date issued en_US
dc.contributor.department American University in Cairo. School of Engineering Interdisciplinary Program en_US
dc.description.irb American University in Cairo Institutional Review Board approval is not necessary for this item, since the research is not concerned with living human beings or bodily tissue samples. en_US
dc.contributor.committeeMember Ramadan, Adham
dc.contributor.committeeMember Hathout, Rania
dc.contributor.committeeMember Abdellatif, Ahmed

Files in this item


This item appears in the following Collection(s)

  • Theses and Dissertations [1518]
    This collection includes theses and dissertations authored by American University in Cairo graduate students.

Show simple item record